Off-label use of medication
is common in many areas of medicine and particularly in dermatology. Off-label
use of medication, whether by prescription or use of samples, creates special
ethical issues that include informed consent, patient autonomy and the
fundamental adage “first, do no harm”. The choice of medication is also
influenced by the patient and appropriate use ultimately depends on a thorough
discussion of the risks and benefits as well as a mutually agreed treatment
Cite this paper
Wolz, M. and Pittelkow, M. (2014) The Ethics of Therapy Selection in Dermatology. International Journal of Clinical Medicine
, 1016-1019. doi: 10.4236/ijcm.2014.516132
 United States v. Caronia, 703 F.3d 149 (2d Cir. 2012).
 Gilhooley, M. (2011) Commercial Speech and Off-Label Drug Uses: What Role for Wide Acceptance, General Recognition and Research Incentives? American Journal of Law & Medicine, 37, 258-277.
 Mamede, S., van Gog, T., van den Berge, K., Rikers, R.M., van Saase, J.L., van Guldener, C., et al. (2010) Effect of Availability Bias and Reflective Reasoning on Diagnostic Accuracy among Internal Medicine Residents. JAMA, 304, 1198-1203. http://dx.doi.org/10.1001/jama.2010.1276
 Alikhan, A., Sockolov, M., Brodell, R. and Feldman, S. (2010) Drug Samples in Dermatology: Special Considerations and Recommendations for the Future. Journal of the American Academy of Dermatology, 62, 1053-1061.http://dx.doi.org/10.1016/j.jaad.2009.07.053
 Chew, K.D., O’Young, T.S., Hazlet, T.K., Bradley, K.A., Maynard, C. and Lessler, D.S. (2000) A Physician Survey of the Effect of Drug Sample Availability on Physician’s Behavior. Journal of General Internal Medicine, 15, 478-483.http://dx.doi.org/10.1046/j.1525-1497.2000.08014.x
 Venkataraman, S. and Stremersch, S. (2007) The Debate on Influencing Doctors’ Decisions: Are Drug Characteristics the Missing Link? Management Science, 53, 1688-1701. http://dx.doi.org/10.1287/mnsc.1070.0718
 Sams, W.M. and Freedberg, I.M. (2000) The Dermatology-Industry Interface: Defining Boundaries. Journal of the American Academy of Dermatology, 43, 550-554. http://dx.doi.org/10.1067/mjd.2000.107502
 Resneck Jr., J.S. and Vanbeek, M. (2010) Individual Drug Sampling Does Not Supplant the Need for Head-to-Head Trials in Dermatology. Journal of the American Academy of Dermatology, 62, 1062-1063. http://dx.doi.org/10.1016/j.jaad.2009.10.023
 Li, V.W., Jaffe, M.P., Li, W.W. and Haynes, H.A. (1998) Off-Label Dermatologic Therapies. Usage, Risks, and Mechanisms. Archives of Dermatology, 134, 1449-1454. http://dx.doi.org/10.1001/archderm.134.11.1449
 Hyman, P.M. and Carvajal, R. (2009) Drugs and Other Product Choices. Dermatologic Therapy, 22, 216-224.http://dx.doi.org/10.1111/j.1529-8019.2009.01234.x
 Payette, M. and Grant-Kels, J.M. (2012) Generic Drugs in Dermatology: Part I. Journal of the American Academy of Dermatology, 66, 343.e1-343.e8.
 Wolz, M. (2013) The Philosopher in the Clinic. International Journal of Dermatology, 52, 629-630.http://dx.doi.org/10.1111/j.1365-4632.2012.05651.x
 Snyder, L. (2012) American College of Physicians Ethics, Professionalism, and Human Rights Committee. American College of Physicians Ethics Manual: Sixth Edition. Annals of Internal Medicine, 156, 73-104.